In patients treated for melanoma, the rate of LC appears to be higher when using anti-PD-1, with rates of 80–96% [79,83,87,89] compared to anti-CTLA4, with rates of 16.5–100% [74,75,85]. This evidence concerns the gene CTLA4 and melanoma.